NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
06/25/2024
Back to search
Official data from USPTO
M MICROBIX
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Quick snapshot
ST13
US500000088004821Class
1, 5, 9, 10, 42, 44, 45
Filing
88004821
Registration
7424197
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
68
Latest update
06/25/2024
Trademark type
Combined
Nice classes
1, 5, 9, 10, 42, 44, 45
Filing date
06/18/2018
Registration date
06/25/2024
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
06/25/2024
Last transaction
06/25/2024
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use, Foreign priority
Drawing code
5
Owner type
03
Owner location
Mississauga, Ontario, CA
Examiner
GOODWIN, KATRINA
Current location
FILE REPOSITORY (FRANCONIA)
Mark description
The mark consists of "MICROBIX" underneath a stylized "M".
Holders and representatives
Holders
Microbix Biosystems Inc.
Representatives
Richard M. LaBarge MARSHALL, GERSTEIN & BORUN LLP
Technical classification
Nice Classes
Class 1Class 5Class 9Class 10Class 42Class 44Class 45
Vienna Codes
No Vienna codes available.
Goods and services
Class 1
Biochemical agents for in vitro and in vivo scientific or diagnostic usevirusesbacteriaparasitespurified and unpurified wholefragmentedfractionated pathogens and pathogenic organisms; Cells and cell culture derived products for in vitro or in vivo scientific or diagnostic usefor production of organismsproteinsnucleic acidscellular fractions used as reagents or antigenstest articlescontrols; antibodies and thrombolytics for in vitro scientific or research use; Biochemicals in the form of monoclonal antibodies for in vitro scientific use; Biochemicals in the form of monoclonal antibodies for research use; Active Pharmaceutical Ingredients to stimulate blood-clot dissolving processes; Microbial antigens and antisera for in vitro diagnostic use
Class 5
urokinase used to treat blood clots; Thrombolytic drugsplasminogen activating drugs and fibrinolytic drugs; urokinase preparations for the restoration of patency to central venous catheters obstructed by clotted blood or fibrin; urokinase preparations for treating pulmonary embolism; urokinase preparations for treating the lysis of acute pulmonary emboli and pulmonary emboli accompanied by unstable hemodynamics; urokinase preparations for treating thrombosis; urokinase preparations for treating coronary artery thrombosis; urokinase preparations for treating myocardial infarction; urokinase preparations for the lysis of thrombi; urokinase preparations for treating peripheral arterial and graft thromboembolic occlusion; urokinase preparations for treating deep vein thrombosis; urokinase preparations for treating pleural effusions; urokinase preparations for treating peripheral arterial occlusion; urokinase preparations for treating ischemic stroke; urokinase preparations for treating lower limb ischemia; test samples used in conjunction with laboratory diagnostics in the nature of biological or biochemical samples used to verify the reliability of laboratory equipment; test samples used in conjunction with assay methods in the nature of biological or biochemical assay samples used to verify the reliability of laboratory tests; Liquidfrozen and lyophilized inactivatednative pathogensincluding whole and fragmented eukaryotesprokaryotesvirusesindependent and in host cellsall for in vitro and in vivo scientific or diagnostic use; inactivatednative pathogensliquidfrozen or lyophilized recombinant DNA and/or RNA preparationseither purified or within host organismsin various bufferssingly and in combinationall for in vitro and in vivo scientific or diagnostic use; Positive controlsreagents for use with nucleic-acid-basedimmunologicother diagnostic tests to confirm proper test operationrun in conjunction with patient samples run to confirmassesstestverify the operation of the test method; proficiency test samples in the nature of biological test samples used to test the proficiency of technicians who use infectious disease diagnostics test systems to determine the pathogenic or biochemical content of samples; Diagnostic reagents in the nature of biotechnology products for medical and veterinary usemicro-organisms for amplification controls; Diagnostic kits for in-vitro scientific and diagnostic use; Laboratory assay kits for scientific and diagnostic use; Biological material for scientific or diagnostic purposesin the nature of serum and plasma from infected and disease state individuals used for verification and validation of human diagnostic assays for such infections and diseases; Biotechnology products for scientific or diagnostic purposesreagents and solutions in the nature of virusesbacteriafungiparasitesderivatives thereof used to researchdevelopmanufacturevalidate infectious disease diagnostic tests; biochemical productsantibodies for scientific or research use; diagnostic reagents containing lyophilized microorganismsreagents containing lyophilized microorganisms all for in-vitro use and for use in biochemistryclinical chemistry and microbiology; diagnostic reagents for scientific research use; diagnostic reagents for medical research use; diagnostic preparations for clinical laboratory use; diagnostic preparations for medical laboratory use; diagnostic preparations for medical research use; diagnostic preparations for scientific research use
Class 9
laboratory instruments for the detection pathogens and toxins in a biological sample for research use; Instruments for the processing of cells and cell derived materialsflow cytometers and flow-based analyzers that detect and analyze nucleic acid content for scientificlaboratorygeneral research use; laboratory instruments that detect pathogens in a biological sample for research use; Instruments for the processing of cells and cell derived materials
Class 10
automated flow cytometer sample introduction accessories used in conjunction with a flow cytometer to deliver biological and chemical samples from single test tubes and multiwell laboratory plates; medical apparatus for the automated analysis of cells in the nature of cytometers for medical diagnostic use; medical apparatus for the automated cytometric analysis of cells in the nature of cytometers for medical diagnostic use; medical apparatus in the nature of cytometers that detect atypia in cells for medical diagnostic use; medical apparatus for automated analysis of nuclear features for the detection of neoplasms and cancer and genetic conditions; apparatus for medical diagnostic uses in the nature of an automated flow cytometer sample introduction accessorya machine which is used in conjunction with a flow cytometer to deliver biological and chemical samples from single test tubes and multi-well laboratory plates
Class 42
Providing diagnostic testing serviceslaboratory tests; production for others of cellscell linesvirusesbacteriapathogensproteinsnucleic acids in whole or in part; Research and development services in the field of process technology used in the manufacture of vaccines; process technology services to be used in the manufacture of a vaccine; biological cell-selection services for biological research purposes; biological research services of delivering energy to a population of biological cells for the purpose of selecting desired cells and negatively selecting undesired cells
Class 44
Animal husbandry services; animal breeding services; sperm- and semen-sexing services in the nature of in vitro fertilization services; biological cell-selection services for medical purposes in the nature of in vitro fertilization services; medical services in the field of in vitro fertilizationservices of delivering energy to a population of biological cells for the purpose of selecting desired cells and negatively selecting undesired cells
Class 45
Licensing of process technology used in the manufacturing of vaccines
Publications
History of USPTO decisions and trademark events.
68 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
06/25/2024
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
04/09/2024
PUBO
PUBLISHED FOR OPPOSITION
04/09/2024
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
03/20/2024
ERRR
ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED
03/01/2024
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
02/22/2024
XAEC
EXAMINER'S AMENDMENT ENTERED
02/20/2024
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
02/20/2024
GNEA
EXAMINERS AMENDMENT E-MAILED
02/20/2024
CNEA
EXAMINERS AMENDMENT -WRITTEN
02/20/2024
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
01/30/2024
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
01/30/2024
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
01/30/2024
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
12/28/2023
GNRT
NON-FINAL ACTION E-MAILED
12/28/2023
CNRT
NON-FINAL ACTION WRITTEN
12/28/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
10/25/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
10/25/2023
ERSI
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
10/24/2023
GNS2
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
07/26/2023
GNSI
INQUIRY TO SUSPENSION E-MAILED
07/26/2023
CNSI
SUSPENSION INQUIRY WRITTEN
07/26/2023
RCCK
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
07/06/2023
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
12/14/2022
GNSL
LETTER OF SUSPENSION E-MAILED
12/14/2022
CNSL
SUSPENSION LETTER WRITTEN
12/14/2022
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
12/12/2022
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
12/12/2022
ALIE
ASSIGNED TO LIE
12/12/2022
ERSI
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
12/05/2022
GNS2
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
06/09/2022
GNSI
INQUIRY TO SUSPENSION E-MAILED
06/09/2022
CNSI
SUSPENSION INQUIRY WRITTEN
06/09/2022
RCCK
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
05/25/2022
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
10/20/2021
GNSL
LETTER OF SUSPENSION E-MAILED
10/20/2021
CNSL
SUSPENSION LETTER WRITTEN
10/20/2021
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
10/12/2021
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
10/12/2021
ERSI
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
10/05/2021
GNS2
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
04/08/2021
GNSI
INQUIRY TO SUSPENSION E-MAILED
04/08/2021
CNSI
SUSPENSION INQUIRY WRITTEN
04/08/2021
RCCK
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
03/24/2021
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
06/12/2020
GNSL
LETTER OF SUSPENSION E-MAILED
06/12/2020
CNSL
SUSPENSION LETTER WRITTEN
06/12/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
06/10/2020
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
06/10/2020
ERSI
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
06/05/2020
GNS2
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
12/09/2019
GNSI
INQUIRY TO SUSPENSION E-MAILED
12/09/2019
CNSI
SUSPENSION INQUIRY WRITTEN
12/09/2019
RCCK
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
12/04/2019
ALIE
ASSIGNED TO LIE
11/15/2019
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
04/24/2019
GNSL
LETTER OF SUSPENSION E-MAILED
04/24/2019
CNSL
SUSPENSION LETTER WRITTEN
04/24/2019
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
04/11/2019
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
04/10/2019
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
04/10/2019
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
10/10/2018
GNRT
NON-FINAL ACTION E-MAILED
10/10/2018
CNRT
NON-FINAL ACTION WRITTEN
10/10/2018
DOCK
ASSIGNED TO EXAMINER
10/04/2018
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
06/22/2018
NWAP
NEW APPLICATION ENTERED
06/21/2018
Continuous trademark protection
Get notified about every new filing that threatens M MICROBIX or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.